New hope for kids with tough brain tumors: First-in-Human trial tests engineered immune cells
NCT ID NCT04510051
Summary
This is a first-in-human safety study testing a new cell therapy for children whose brain tumors have come back or stopped responding to standard treatments. Doctors will collect a child's own immune cells, engineer them in a lab to better target a specific protein on the tumor, and then infuse them back into the fluid around the brain. The main goal is to see if this combined approach is safe and to learn about its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT BRAIN NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
C.S. Mott Children's Hospital, University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital Los Angeles
RECRUITINGLos Angeles, California, 90027, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.